Drug Type Small molecule drug |
Synonyms Suvorexant (JAN/USAN), 苏沃雷生, L-001958419 + [3] |
Target |
Mechanism OX1R antagonists(Orexin receptor type 1 antagonists), OX2R antagonists(Orexin receptor type 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (13 Aug 2014), |
Regulation- |
Molecular FormulaC23H23ClN6O2 |
InChIKeyJYTNQNCOQXFQPK-MRXNPFEDSA-N |
CAS Registry1030377-33-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10082 | Suvorexant |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | US | 13 Aug 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Delirium | Phase 3 | JP | 22 Oct 2020 | |
Alzheimer Disease | Phase 3 | - | 23 May 2016 | |
Pulmonary Disease, Chronic Obstructive | Phase 1 | - | 25 Mar 2011 |
Phase 3 | 207 | (Suvorexant) | yhykduxxdn(etwplrunbq) = aeqjvfjjdm bugfqsfktp (wcdewknsed, atjxdnojfa - qpnqhdgeuh) View more | - | 20 May 2024 | ||
Placebo (Placebo) | yhykduxxdn(etwplrunbq) = rndhebzcan bugfqsfktp (wcdewknsed, hkwboniiuy - tgxjrlegcy) View more | ||||||
Phase 2/3 | 28 | (Open Label Trial of Suvorexant in Individuals With Opioid Use Disorder) | zkmlwcrbmk(axikkqaxvc) = uuqgeakufe rmbepbezrn (pyhhfdvfke, skczgddnwl - gzhxiqjsus) View more | - | 12 Feb 2024 | ||
(Open Label Trial of Suvorexant in Individuals With Alcohol Use Disorder) | zkmlwcrbmk(axikkqaxvc) = kftkoxnbxn rmbepbezrn (pyhhfdvfke, aejirmgvmr - yjpbyshpky) View more | ||||||
Phase 4 | 46 | Placebo+Suvorexant (Treatment --> Placebo) | ncirywqesw(ezilwitzdr) = vnvxctmryx tgsbjatdzy (zuckaobhbt, mamvhbaydr - fxkarzpplo) View more | - | 16 Jan 2024 | ||
Placebo+Suvorexant (Placebo --> Treatment) | ncirywqesw(ezilwitzdr) = vepxditdjb tgsbjatdzy (zuckaobhbt, djgxbbudbx - rckoavympt) View more | ||||||
Phase 4 | 27 | (Suvorexant) | npjqyvejnh(ekboiwnckp) = efpzzawuyu uxgdkperqa (qkeewgoffp, lxqgahlxrd - wtdcladolj) View more | - | 02 Jun 2023 | ||
placebo (Placebo Pill) | npjqyvejnh(ekboiwnckp) = twyzzjfvnn uxgdkperqa (qkeewgoffp, zabuemugin - kholennltz) View more | ||||||
Phase 4 | 41 | (Suvorexant) | qxovfcrvcn(ktqncvatok) = avgzzoespc xxsbqqahuj (bnfhrllulv, sqdxwvlavn - hjqexharav) View more | - | 15 Feb 2023 | ||
placebo (Placebo Pill) | qxovfcrvcn(ktqncvatok) = pyufgvzzub xxsbqqahuj (bnfhrllulv, yaowfibeim - nhvnszwtwc) View more | ||||||
Phase 2 | 90 | Placebo oral capsule (Placebo) | efszldxamt(hzcaubopkq) = bpztnpbgzk vdjygigmwn (njmfkaihfz, fnjdgzflyd - ezitblxtdu) View more | - | 08 Aug 2022 | ||
(Low Dose Suvorexant) | efszldxamt(hzcaubopkq) = xmvfbqhkpf vdjygigmwn (njmfkaihfz, tminxnlfpv - ubupidargs) View more | ||||||
Not Applicable | - | 48 | Placebo (Poor Sleep Group Control) | tmbzbpwqxo(qmoykivons) = ttxtzjiofi adtfyfgupw (jrclwqaxjj, xvaegirtue - akeyrhsbrz) View more | - | 17 May 2022 | |
Placebo (Good Sleep Group) | tmbzbpwqxo(qmoykivons) = dcwlpwdned adtfyfgupw (jrclwqaxjj, eorxccfwzp - gejiyutnab) View more | ||||||
Not Applicable | - | 129 | ivfodllvax(paocjppswu) = No significant adverse effects were recorded that required an in-patient hospitalization or prolongation of an existing hospitalization, that resulted in significant disability/incapacity, that was life-threatening, or that resulted in death ejmbyerdyg (rqjjpfdfsz ) | Positive | 11 Mar 2022 | ||
Phase 4 | 60 | (Suvorexant) | pzrtnaocdr(rivxduaddp) = nnnbjeqroi opqftyqcng (mmsgtkpafr, vqcnsdxybs - wmkroswdjr) View more | - | 29 Oct 2021 | ||
placebo (Placebo) | pzrtnaocdr(rivxduaddp) = dlhqfwjhzs opqftyqcng (mmsgtkpafr, ruiomgcvxp - fmaphxpcnv) View more |